Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Kane Biotech appoints renowned wound care and biofilms expert, Dr. Gregory Schultz, as scientific advisor

Kane Biotech (TSX-V:KNE) appointed wound care and biofilms expert, Dr. Gregory Schultz, as a scientific advisor. Dr. Schultz is the director of the Institute for Wound Research and professor of obstetrics and gynecology...

August 12, 2020

Markets

AGP ups Itamar Medical PT to $28 from $22.75

Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $28 from $22.75 after the company’s second quarter results beat expectations. However, the stock closed at $22.02, down $3.84, on Aug...

August 12, 2020

Developments

Hepion CRV431 antiviral benefits published in PLOS ONE

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that the peer-reviewed journal, PLOS ONE, has published a paper highlighting the antiviral effects of CRV431. Co-authored by Hepion’s CSO, Dr. Daren Ure and CEO...

August 12, 2020

Markets

BTIG ups Sensenonics to buy; PT to $1

BTIG upgraded Sensenonics Holdings (NYSE American:SENS) to “buy” from “neutral” with a price target of $1, citing a commercial collaboration with Ascensia Diabetes Care, a financing agreement with Ascensia’s parent, PHC...

August 11, 2020

Developments

Ocugen OCU400 gets fourth FDA orphan drug designation for retinal disease

Ocugen’s (NASDAQ:OCGN) OCU400 received FDA orphan drug designation for the treatment of PDE6B gene mutation-associated retinal disease. OCU400 consists of a nuclear hormone receptor gene, NR2E3, which is delivered to...

August 10, 2020

Developments

Omeros reports positive results from COVID-19-associated ARDS trial

Omeros (NASDAQ:OMER) reported positive results from a study evaluating narsoplimab for the treatment of COVID-19-associated acute respiratory distress syndrome (ARDS). Narsoplimab is a human monoclonal antibody that is...

August 10, 2020

Developments

Seres SER-109 meets primary endpoint in Phase 3 study of C. difficile infection

Seres Therapeutics (NASDAQ:MCRB) reported positive topline results from its Phase 3 trial evaluating SER-109 for the treatment of recurrent C. difficile infection. The study enrolled 182 patients with multiply...

August 10, 2020

Developments

Kazia gets FDA rare pediatric disease designation for paxalisib

Kazia Therapeutics (NASDAQ:KZIA) received FDA rare pediatric disease designation for paxalisib for the treatment of diffuse intrinsic pontine glioma (DIPG). Paxalisib is currently in a Phase 1 trial for DIPG. Positive...

August 7, 2020

Executive Moves

Pacific Biosciences names Christian Henry as president and CEO

Christian Henry Pacific Biosciences (NASDAQ:PACB) appointed Christian Henry as president and CEO, effective Sept. 14. Mr. Henry will replace Michael Hunkapiller, who will retire at the end of 2020. Current...

August 7, 2020

Developments

Clovis enrolls first patient in Phase 2 portion of gynecologic cancer trial

Clovis Oncology (NASDAQ:CLVS) enrolled the first patient in the Phase 2 portion of its LIO-1 trial evaluating lucitanib for the treatment of gynecologic cancers. The trial is designed to evaluate the safety and efficacy...

August 6, 2020

Developments

FDA clears Surmodics’ Sublime dilatation catheter

Surmodics (NASDAQ:SRDX) received FDA 510(k) clearance for its Sublime radial access dilatation catheter. The company noted that at 250 cm, the Sublime catheter has the longest working length of currently available...

August 6, 2020

Developments

MediciNova reports positive results from Phase 2 alcohol use disorder trial

MediciNova (NASDAQ:MNOV) reported positive results from its Phase 2 trial evaluating ibudilast for the treatment of alcohol use disorder (AUD). Ibudilast has been marketed in Japan and Korea since 1989 to treat post...

August 6, 2020

Subscribe